Which ATTRibute-CM poster topics will BridgeBio (BBIO) share at ACC on March 28-30, 2026?

BridgeBio will present three posters covering sTTR and KCCQ-OS changes, early sTTR increases and long-term heart-failure health status, and U.S. treatment patterns and preferences. According to the company, posters appear on March 28 and March 30 with named presenters and times.

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

BridgeBio (NASDAQ: BBIO) will present long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial of acoramidis at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28-30, 2026.

A late-breaking oral presentation on survival and disease stabilization is scheduled for March 30 at 2:33 pm CT, plus three posters on biomarker, health-status and real-world survey findings on March 28 and March 30.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – BBIO

+1.55%

+1.55% News Effect

On the day this news was published, BBIO gained 1.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement highlights upcoming long-term efficacy and safety data for acoramidis in ATTR-CM f...

Analysis

This announcement highlights upcoming long-term efficacy and safety data for acoramidis in ATTR-CM from the ATTRibute-CM open-label extension, to be presented at a major cardiology meeting. It reinforces BridgeBio’s emphasis on later-stage cardiomyopathy programs, complementing other recent Phase 3 updates. Investors may watch for detailed survival, disease stabilization, and quality-of-life metrics, as well as how these findings integrate with prior ATTRibute-CM results and broader commercial plans for the program.

Key Figures

Phase: Phase 3 Conference dates: March 28–30, 2026 Number of posters: 3 posters +4 more

7 metrics

Phase Phase 3 ATTRibute-CM study of acoramidis

Conference dates March 28–30, 2026 ACC Annual Scientific Sessions & Expo

Number of posters 3 posters Additional OLE data and real-world survey findings

Oral presentation time 2:33 pm CT Long-term survival and disease stabilization session on March 30

Poster time 1 12:30 pm CT First poster session on March 28

Poster time 2 3:30 pm CT Second poster session on March 28

Poster time 3 9:30 am CT Third poster session on March 30

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 11	Phase 3 interim data	Positive	-3.9%	Positive Phase 3 FORTIFY interim efficacy and safety results for BBP-418 in LGMD2I/R9.
Mar 04	Data presentation plans	Positive	+3.1%	Announcement of additional Phase 3 FORTIFY data presentations at a major neuromuscular conference.
Feb 24	Earnings and pipeline	Positive	-2.6%	Strong Q4/FY 2025 revenue, key product sales, cash balance, and new convertible notes.
Feb 23	Investor conferences	Neutral	-0.3%	Participation in several March 2026 healthcare investor conferences with fireside chats.
Feb 17	Inducement equity grants	Neutral	-2.5%	Inducement RSU grants to new employees under Nasdaq Listing Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: some positive clinical and earnings updates were followed by share price declines, while other data presentations aligned with modest gains.

Recent Company History

Over the past months, BridgeBio reported multiple milestones, including positive Phase 3 FORTIFY interim data on Mar 11, 2026 and plans for an NDA, plus additional FORTIFY data presentations announced on Mar 4, 2026. Q4 and full-year 2025 results on Feb 24, 2026 highlighted substantial revenue and financing activity. Other releases covered investor conference participation and inducement grants. Today’s announcement fits the pattern of showcasing later-stage clinical data and follow-on analyses at major scientific meetings.

Key Terms

open-label extension, phase 3, transthyretin amyloid cardiomyopathy, kansas city cardiomyopathy questionnaire, +1 more

5 terms

open-label extension medical

"long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

phase 3 medical

"the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

transthyretin amyloid cardiomyopathy medical

"Score in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)"

Transthyretin amyloid cardiomyopathy is a progressive heart condition where a normally circulating protein, transthyretin, misfolds and forms sticky clumps that build up in the heart, making it stiff and less able to pump. For investors, it matters because diagnosing and treating this disease drives demand for specialized drugs, tests and long-term care, creating a distinct market opportunity tied to regulatory approvals, pricing and reimbursement decisions.

kansas city cardiomyopathy questionnaire medical

"Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in Patients"

A patient questionnaire that measures symptoms, physical limitations and quality of life for people with heart failure; it gives a standardized score that reflects how the condition affects daily living. Investors care because the score is often used as a clinical-trial endpoint or regulatory evidence to show a treatment actually improves patients’ lives, similar to a customer-satisfaction rating that can influence approval, reimbursement and market uptake.

real-world survey medical

"three posters on additional OLE data and real-world survey findings"

A real-world survey gathers information from patients, doctors, or other users about how a therapy, device, or service performs in everyday practice rather than in controlled trials. Think of it as collecting customer feedback from actual use on the street rather than in a test kitchen; for investors it reveals real demand, perceived benefits or problems, and adoption trends that can affect sales, regulatory outlook, and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/23/2026 - 07:30 AM

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings.

Late-Breaking Oral Presentation:
Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM
Presenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine
Date: Monday, March 30 at 2:33 pm CT

Posters:
Long-Term Benefits With Acoramidis on Serum Transthyretin Concentrations and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Presenter: Sarah Cuddy, M.D., Brigham and Women's Hospital
Date: Saturday, March 28 at 12:30 pm CT

Association Between Early Increase in sTTR with Acoramidis and Long-term Effects on Heart Failure – Related Health Status in ATTR-CM: Results from ATTRibute-CM
Presenter: Jan Griffin, M.D., Medical University of South Carolina
Date: Saturday, March 28 at 3:30 pm CT

Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey
Presenter: Jill Waldron, MSN, GNP, MS, University of Utah
Date: Monday, March 30 at 9:30 am CT

About Attruby™ (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

What will BridgeBio (BBIO) present at ACC 2026 on March 30 regarding ATTRibute-CM?

BridgeBio will present a late-breaking oral session on long-term survival benefits and disease stabilization with acoramidis. According to the company, the oral presentation is scheduled for March 30, 2026 at 2:33 pm CT and reports OLE trial efficacy and safety data.

Who are the presenters for BridgeBio's (BBIO) late-breaking oral and poster sessions at ACC 2026?

The late-breaking oral presenter is Prem Soman, M.D., Ph.D.; poster presenters include Sarah Cuddy, Jan Griffin and Jill Waldron. According to the company, each presenter represents an academic center and specific poster times are scheduled March 28 and March 30.

When and where is BridgeBio's (BBIO) late-breaking oral presentation on acoramidis at ACC 2026?

The late-breaking oral presentation will occur on Monday, March 30, 2026 at 2:33 pm CT in New Orleans during the ACC Annual Scientific Sessions. According to the company, the talk will present long-term efficacy and safety results from the ATTRibute-CM OLE.

How can investors learn the key takeaways from BridgeBio's (BBIO) ACC 2026 presentations on ATTR-CM?

Investors can review the late-breaking oral presentation and three posters scheduled March 28–30, 2026 at ACC in New Orleans for detailed OLE findings. According to the company, the sessions will report long-term efficacy, safety, biomarker and real-world survey results for acoramidis.